Alamar Biosciences presented extensive data from its NULISA platform at the AAIC 2026 conference, highlighting advances in blood-based biomarkers for Alzheimer's detection and staging. The company emphasized new findings on eMTBR-Tau and BD-pTau217, two highly specific blood markers, which improve disease differentiation and early detection when combined. Their multiplex protein profiling technology allows simultaneous measurement of tau pathology, neuroinflammation, and neurodegeneration markers, offering deeper insights into Alzheimer's progression. Alamar also hosted a workshop to discuss these innovations, signaling growing adoption of their technology in Alzheimer's research.
PennantPark Investment (PNNT) and PennantPark Floating Rate Capital (PFLT) reported Q3 FY26 results with differing financial health despite shared management. PFLT, the larger fund, has a cleaner portfolio with 99% floating-rate debt and a dividend f...
Qualcomm's stock has been upgraded back to Buy after a sharp correction brought its valuation to a more reasonable 17 times forward earnings. Despite near-term challenges such as weak Chinese smartphone demand, rising component costs, and Apple's shi...
The Nakamoto upgrade on the Stacks network, activated in October 2024, links every Stacks transaction finality directly to Bitcoin blocks, meaning reversing a Stacks transaction now requires rewriting Bitcoin itself. This upgrade ensures 100% Bitcoin...
Since President Trump's second term began in January 2025, the S&P 500 has gained about 28%, despite a sharp 12% drop in April following new tariffs. Trump's investment accounts saw over 1,000 trades in June alone, involving millions in major stocks ...
Duolingo is recognized as a disruptive leader in EdTech, expanding beyond language learning with ambitions to become the top AI-powered education platform. Despite recent stock price declines, analysts view this as a valuation correction rather than ...
